Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration

Jennifer Gass(Jacksonville College), Ashley Cannon(Jacksonville College), Ian R. Mackenzie(University of British Columbia), Bradley F. Boeve(Mayo Clinic), Matt Baker(Jacksonville College), Jennifer Adamson(Jacksonville College), Richard Crook(Jacksonville College), Stacey Melquist(Jacksonville College), Karen M. Kuntz(Mayo Clinic), Ron Petersen(Mayo Clinic), Keith A. Josephs(Mayo Clinic), Stuart Pickering‐Brown(University of Manchester), Neill R. Graff‐Radford(Jacksonville College), Ryan J. Uitti(Jacksonville College), Dennis W. Dickson(Jacksonville College), Zbigniew K. Wszołek(Jacksonville College), John Gonzalez(Jacksonville College), Thomas G. Beach(Banner Sun Health Research Institute), Eileen H. Bigio(Northwestern University), Nancy Johnson(Northwestern University), Sandra Weıntraub(Northwestern University), Marsel Mesulam(Northwestern University), Charles L. White(The University of Texas Southwestern Medical Center), Bryan K. Woodruff(Mayo Clinic in Arizona), Richard J. Caselli(Mayo Clinic in Arizona), Ging‐Yuek Robin Hsiung(University of British Columbia), Howard Feldman(University of British Columbia), Dave Knopman(Mayo Clinic), Mike Hutton(Jacksonville College), Rosa Rademakers(Jacksonville College)
Human Molecular Genetics
September 1, 2006
Cited by 578

Abstract

Null mutations in the progranulin gene (PGRN) were recently reported to cause tau-negative frontotemporal dementia linked to chromosome 17. We assessed the genetic contribution of PGRN mutations in an extended population of patients with frontotemporal lobar degeneration (FTLD) (N=378). Mutations were identified in 10% of the total FTLD population and 23% of patients with a positive family history. This mutation frequency dropped to 5% when analysis was restricted to an unbiased FTLD subpopulation (N=167) derived from patients referred to Alzheimer's Disease Research Centers (ADRC). Among the ADRC patients, PGRN mutations were equally frequent as mutations in the tau gene (MAPT). We identified 23 different pathogenic PGRN mutations, including a total of 21 nonsense, frameshift and splice-site mutations that cause premature termination of the coding sequence and degradation of the mutant RNA by nonsense-mediated decay. We also observed an unusual splice-site mutation in the exon 1 5' splice site, which leads to loss of the Kozac sequence, and a missense mutation in the hydrophobic core of the PGRN signal peptide. Both mutations revealed novel mechanisms that result in loss of functional PGRN. One mutation, c.1477C>T (p.Arg493X), was detected in eight independently ascertained familial FTLD patients who were shown to share a common extended haplotype over the PGRN genomic region. Clinical examination of patients with PGRN mutations revealed highly variable onset ages with language dysfunction as a common presenting symptom. Neuropathological examination showed FTLD with ubiquitin-positive cytoplasmic and intranuclear inclusions in all PGRN mutation carriers.


Related Papers

No related papers found

Powered by citation graph analysis